{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:14:28Z","timestamp":1792088068811,"version":"4.4.0"},"reference-count":18,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2012,10,1]]},"abstract":"\n \n Background:<\/jats:italic>\n <\/jats:title>\n \n Topical medicaments are a common cause of allergic contact dermatitis. This study will evaluate the prevalence of contact allergy to a wide array of topical medicaments at the Ottawa Patch Test Clinic.<\/jats:bold>\n <\/jats:p>\n <\/jats:sec>\n \n \n Objectives:<\/jats:italic>\n <\/jats:title>\n \n The objectives of this study are to report the results of positive patch testing to topical medicaments at the Ottawa Patch Test Clinic and identify common sensitizers in topical medicaments.<\/jats:bold>\n <\/jats:p>\n <\/jats:sec>\n \n \n Methods:<\/jats:italic>\n <\/jats:title>\n \n Patients were tested with the standard North American Contact Dermatitis screening series of 70 allergens plus supplementary allergens when indicated. A retrospective chart review of patients positive to topical medicaments between January 1, 2000, and September 30, 2010, was undertaken.<\/jats:bold>\n <\/jats:p>\n <\/jats:sec>\n \n \n Results:<\/jats:italic>\n <\/jats:title>\n \n The average age of patients was 49.5 years. Thirty-four percent were atopic. Common sensitizers included topical antibiotics (58%), steroids (30%), anesthetics (6%), and antifungals (6%). Patch testing showed that 61% of patients tested positive to antibiotics, 21% to topical steroids, 17% tested positive to topical anesthetics, and 1% tested positive to topical antifungals. The most common reactions were to bacitracin (44%) and neomycin (29%). The most common steroid screener was tixocortol-17-pivalate (group A) (19%), and the most common local anesthetic was lidocaine (12%).<\/jats:bold>\n <\/jats:p>\n <\/jats:sec>\n \n \n Conclusions:<\/jats:italic>\n <\/jats:title>\n \n Topical medicaments of all kinds are common causes of allergic contact dermatitis. Those that are more readily available, in over-the-counter preparations, are the most frequent culprits.<\/jats:bold>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/der.0b013e31826e443c","type":"journal-article","created":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T12:03:59Z","timestamp":1397649839000},"page":"210-213","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":30,"title":["Contact Dermatitis to Topical Medicaments: A Retrospective Chart Review From the Ottawa Hospital Patch Test Clinic"],"prefix":"10.1177","volume":"23","author":[{"given":"Shanna","family":"Spring","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Pratt","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chaplin","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2012,10,1]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.07.050"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1989.tb04730.x"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2009.05.003"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1586\/17469872.3.1.37"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1268"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.2310\/6620.2009.08097"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.2310\/6620.2007.06060"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2009.01666.x"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2008.01499.x"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1998.tb05924.x"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.2310\/6620.2007.06072"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.2310\/6620.2006.05048"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0536.2000.042002059.x"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1117"},{"issue":"4","key":"e_1_3_1_16_2","first-page":"176","article-title":"North American contact dermatitis group patch-test results, 2001-2002 study period","volume":"15","author":"Pratt MD","year":"2004","unstructured":"Pratt MD, , Belsito DV, , DeLeo VA, et al. North American contact dermatitis group patch-test results, 2001-2002 study period. Dermatitis, 2004; 15 (4): 176-183.","journal-title":"Dermatitis"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2006.01084.x"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04662.x"},{"key":"e_1_3_1_19_2","first-page":"972","article-title":"Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs","volume":"276","author":"Smack DP","year":"1996","unstructured":"Smack DP, , Harrington AC, , Dunn C, et al. Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs. bacitracin ointment. A randomized control trial. JAMA, 1996; 276: 972-977.","journal-title":"bacitracin ointment. A randomized control trial. JAMA"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0b013e31826e443c","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1097\/DER.0b013e31826e443c","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0b013e31826e443c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:07:53Z","timestamp":1777399673000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1097\/DER.0b013e31826e443c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,1]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10,1]]}},"alternative-id":["10.1097\/DER.0b013e31826e443c"],"URL":"https:\/\/doi.org\/10.1097\/der.0b013e31826e443c","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,1]]}}}